Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Somatic mutations in the epidermal growth factor receptor (EGFR) gene are key in non-small cell lung cancer (NSCLC) targeted treatments.
• The EGFR T790M mutation develops in about 50% of patients resistant to tyrosine kinase inhibitors (TKIs).
• Detecting T790M in tumor tissue is difficult due to tumor heterogeneity, low mutation levels, and re-biopsy challenges in advanced NSCLC.

Purpose of the Study:

• To review commonly used platforms for detecting the EGFR T790M mutation.
• To compare methods for analyzing EGFR T790M in both tumor tissue and plasma samples.
• To highlight the importance of molecular testing in NSCLC management.

Main Methods:

• Review of existing literature on EGFR T790M detection platforms.
• Analysis of methods for detecting mutations in tumor tissue.
• Evaluation of circulating tumor DNA (ctDNA) as a non-invasive alternative for mutational analysis.

Main Results:

• Circulating tumor DNA (ctDNA) offers a non-invasive approach for EGFR T790M mutation detection.
• The presence of EGFR mutations in ctDNA can predict response to EGFR TKIs.
• Standardized kits and targeted analysis have improved the accuracy of EGFR mutation detection platforms.

Conclusions:

• Molecular testing for EGFR mutations is a standard of care in NSCLC.
• ctDNA analysis presents a viable alternative to tissue biopsy for detecting resistance mutations like EGFR T790M.
• Accurate detection platforms are essential for guiding personalized treatment strategies in NSCLC.